News

FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication

Publish date: February 10, 2014

 

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Risk of stopping dual-antiplatelet therapy after stenting depends upon the reason
MDedge Emergency Medicine
Gender-specific biomarker thresholds urged in MI diagnosis
MDedge Emergency Medicine
Novel two-biomarker strategy permits early ACS rule-out
MDedge Emergency Medicine
Prehospital bivalirudin reduced bleeding with PCI
MDedge Emergency Medicine
Studies question benefits of induced hypothermia after cardiac arrest
MDedge Emergency Medicine
Noninvasive coronary test accurate for lesion-specific ischemia
MDedge Emergency Medicine
Chest pain traits didn’t identify MI in women
MDedge Emergency Medicine
Work cardiac resuscitations in the field, not the ambulance
MDedge Emergency Medicine
Mechanical device as effective as manual chest compressions
MDedge Emergency Medicine
FDA panel rejects rivaroxaban again for acute coronary syndrome
MDedge Emergency Medicine

Related Articles